These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 9581161

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Terazosin for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 1994 Feb 18; 36(916):15-6. PubMed ID: 7508075
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Terazosin for BPH.
    Jerant AF.
    J Fam Pract; 1995 Mar 18; 40(3):222-3. PubMed ID: 7533204
    [No Abstract] [Full Text] [Related]

  • 5. [New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
    Wien Klin Wochenschr; 1995 Mar 18; 107(15):472-6. PubMed ID: 7545857
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Terazosin now indicated for benign prostatic hyperplasia.
    Am J Hosp Pharm; 1994 Jan 01; 51(1):25. PubMed ID: 7510930
    [No Abstract] [Full Text] [Related]

  • 9. [Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
    Yang MG, Zhao XK.
    Zhonghua Nan Ke Xue; 2007 Sep 01; 13(9):830-4. PubMed ID: 17929564
    [Abstract] [Full Text] [Related]

  • 10. Terazosin, finasteride, or both in benign prostatic hyperplasia.
    Thien T, Lenders JW.
    N Engl J Med; 1997 Jan 23; 336(4):294. PubMed ID: 9005318
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Terazosine in the treatment of benign prostatic hypertrophy].
    Caine M.
    J Urol (Paris); 1993 Jan 23; 99(6):311-3. PubMed ID: 7516376
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J.
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug 23; 27(8):392-7. PubMed ID: 2477339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lichenoid drug eruption to terazosin.
    Koh MJ, Seah PP, Tay YK, Mancer K.
    Br J Dermatol; 2008 Feb 23; 158(2):426-7. PubMed ID: 18047505
    [No Abstract] [Full Text] [Related]

  • 19. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
    Guthrie R.
    J Fam Pract; 1994 Aug 23; 39(2):129-33. PubMed ID: 7520053
    [Abstract] [Full Text] [Related]

  • 20. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Dunzendorfer U.
    Arzneimittelforschung; 1989 Oct 23; 39(10):1289-91. PubMed ID: 2482025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.